Mirati Therapeutics Inc
MRTX
56.49USD-0.20Â (-0.35%)Market ClosedWatchlist
Market Summary
USD56.49-0.20
Market Closed-0.35%
MRTX Stock Price
View Fullscreen
MRTX RSI Chart
MRTX Valuation
MRTX Price/Sales (Trailing)
MRTX Profitability
MRTX Fundamentals
MRTX Revenue
MRTX Earnings
Price Action
Last 7 days
-1.0%
Last 30 days
0.9%
Last 90 days
58.4%
Trailing 12 Months
28.8%
How does MRTX drawdown profile look like?
MRTX Financial Health
MRTX Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2023 | 18.9M | 27.2M | 38.2M | 0 |
| 2022 | 57.2M | 42.3M | 27.4M | 12.4M |
| 2021 | 28.1M | 42.7M | 57.4M | 72.1M |
| 2020 | 5.9M | 8.4M | 10.9M | 13.4M |
| 2019 | 4.7M | 5.3M | 6.3M | 3.3M |
| 2018 | 0 | 0 | 0 | 12.9M |
| 2017 | 0 | 0 | 0 | 0 |
| 2016 | 0 | 0 | 0 | 0 |
| 2015 | 0 | 0 | 0 | 0 |
| 2014 | 0 | 0 | 0 | 0 |
| 2013 | 0 | 0 | 0 | 0 |
| 2012 | 0 | 0 | 0 | 0 |
| 2011 | 0 | 0 | 0 | 3.1M |
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for MRTX
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
| Sep 08, 2023 | ondrey aaron | acquired | 299,972 | 35.66 | 8,412 | interim cfo |
| Sep 08, 2023 | christensen jamie | sold | -85,084 | 35.63 | -2,388 | evp & chief scientific officer |
| Aug 11, 2023 | boxer capital, llc | bought | 33,400,000 | 27.8 | 1,201,440 | - |
| Aug 11, 2023 | boxer capital, llc | bought | 1,599,420 | 27.8 | 57,533 | - |
| Aug 11, 2023 | hasnain faheem | bought | 299,990 | 27.8 | 10,791 | - |
| Aug 09, 2023 | stelzer laurie | acquired | 824,989 | 37.00 | 22,297 | chief financial officer |
| Aug 09, 2023 | hickey benjamin | acquired | 824,989 | 37.00 | 22,297 | evp, chief commercial officer |
| Aug 09, 2023 | christensen jamie | acquired | 824,989 | 37.00 | 22,297 | evp & chief scientific officer |
| Aug 09, 2023 | moriarty john b | acquired | 824,989 | 37.00 | 22,297 | chief legal officer |
| Aug 09, 2023 | sandler alan b. | acquired | 824,989 | 37.00 | 22,297 | chief medical officer |
Which funds bought or sold MRTX recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
| Dec 06, 2023 | CITIGROUP INC | added | 132 | 4,421,260 | 6,867,410 | -% |
| Nov 30, 2023 | Neo Ivy Capital Management | new | - | 1,077,000 | 1,077,000 | 0.47% |
| Nov 24, 2023 | DEUTSCHE BANK AG\ | added | 2.99 | 2,056,290 | 10,566,000 | 0.01% |
| Nov 21, 2023 | COMERICA BANK | reduced | -91.11 | -54,767 | 56,233 | -% |
| Nov 21, 2023 | Walleye Trading LLC | new | - | 30,448 | 30,448 | -% |
| Nov 17, 2023 | JACOBS LEVY EQUITY MANAGEMENT, INC | sold off | -100 | -7,056,910 | - | -% |
| Nov 16, 2023 | Creative Planning | new | - | 6,534 | 6,534 | -% |
| Nov 16, 2023 | Financial Gravity Asset Management, Inc. | sold off | -100 | -10.00 | 8.00 | -% |
| Nov 15, 2023 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | added | 63.49 | 1,935,000 | 3,927,500 | -% |
| Nov 15, 2023 | HARBOUR INVESTMENTS, INC. | sold off | -100 | -3,613 | - | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Mirati Therapeutics Inc
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Oct 12, 2023 | boxer capital, llc | 4.8% | 3,534,249 | SC 13D/A | |
| Oct 02, 2023 | ecor1 capital, llc | 8.5% | 5,748,399 | SC 13G | |
| Aug 16, 2023 | boxer capital, llc | 4.8% | 3,534,249 | SC 13D/A | |
| Feb 14, 2023 | armistice capital, llc | 6.06% | 3,488,000 | SC 13G | |
| Feb 14, 2023 | avoro capital advisors llc | 9.6% | 5,555,555 | SC 13G/A | |
| Feb 14, 2023 | rtw investments, lp | 6.3% | 3,643,114 | SC 13G | |
| Feb 14, 2023 | perceptive advisors llc | 3.8% | 2,191,425 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 8.64% | 4,973,888 | SC 13G/A | |
| Feb 06, 2023 | wellington management group llp | 5.24% | 3,016,335 | SC 13G/A | |
| Feb 15, 2022 | perceptive advisors llc | 5.9% | 3,283,783 | SC 13G/A |
Recent SEC filings of Mirati Therapeutics Inc
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Dec 06, 2023 | DEFA14A | DEFA14A | |
| Dec 01, 2023 | DEFA14A | DEFA14A | |
| Nov 24, 2023 | 8-K | Current Report | |
| Nov 15, 2023 | DEFA14A | DEFA14A | |
| Nov 13, 2023 | 8-K | Current Report | |
| Nov 06, 2023 | 10-Q | Quarterly Report | |
| Nov 06, 2023 | 8-K | Current Report | |
| Nov 02, 2023 | DEFM14A | DEFM14A | |
| Oct 23, 2023 | PREM14A | PREM14A | |
| Oct 13, 2023 | DEFA14A | DEFA14A |
Peers (Alternatives to Mirati Therapeutics Inc)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
HILS | 31.5B | - | 6.13% | 411799.31% | -3.7K | 218.4K | - | -102.45% |
MRNA | 30.6B | 10.7B | 12.59% | -56.51% | -8.83 | 2.87 | -53.67% | -129.46% |
ALNY | 21.3B | 1.7B | 0.38% | -28.56% | -41.84 | 12.38 | 79.37% | 56.87% |
BMRN | 17.5B | 2.3B | 8.71% | -10.95% | 119.09 | 7.58 | 15.05% | 75.21% |
INCY | 12.3B | 3.6B | 1.18% | -34.97% | 28.84 | 3.4 | 8.35% | -51.49% |
| MID-CAP | ||||||||
APLS | 7.4B | 272.9M | 33.62% | 24.68% | -12.26 | 27.23 | 141.38% | 4.43% |
BBIO | 5.7B | - | 10.65% | 240.88% | -9.69 | 48.33 | 54.84% | -12.96% |
ACAD | 3.4B | 631.9M | -9.53% | 43.40% | -23.12 | 5.44 | 23.54% | 31.53% |
AXSM | 3.3B | 223.4M | 14.00% | -9.85% | -16.45 | 14.86 | - | -26.24% |
ARWR | 2.6B | 240.7M | -11.63% | -24.14% | -12.52 | 10.67 | -1.03% | -16.59% |
| SMALL-CAP | ||||||||
CPRX | 1.5B | 348.4M | 12.92% | -15.71% | 24.33 | 4.33 | 81.69% | -7.29% |
NVAX | 661.3M | 1.0B | -18.09% | -67.84% | -1.2 | 0.63 | -43.15% | 58.48% |
INO | 100.5M | 6.4M | - | -79.35% | -0.61 | 15.6 | -44.11% | 50.48% |
IBIO | 37.6M | - | 385.71% | 119.35% | -0.58 | - | - | -29.23% |
CRBP | 23.7M | - | 40.31% | 4064.72% | -0.5 | - | - | -13.74% |
Mirati Therapeutics Inc News
Latest updates
Financials for Mirati Therapeutics Inc
Income Statement (Last 12 Months)
| Income Statement (Quarterly) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Revenue | 19.8% | 16,400,000 | 13,690,000 | 7,167,000 | 934,000 | 5,431,000 | 5,362,000 | 2,830,500 | 299,000 | 71,793,000 | 48,431,333 | 25,069,667 | 1,708,000 | 11,424,000 | 7,791,333 | 4,158,667 | 526,000 | 988,000 | 577,000 | 1,244,000 | 3,459,000 | - |
| Operating Expenses | -6.2% | 188,454,000 | 200,960,000 | 200,990,000 | 212,657,000 | 191,874,000 | 182,567,000 | 184,927,000 | 197,374,000 | 151,292,000 | 164,186,000 | 132,421,000 | 108,043,000 | 100,102,000 | 84,862,000 | 89,754,000 | 75,173,000 | 58,047,000 | 48,218,000 | 44,002,000 | 33,131,000 | 28,939,000 |
| S&GA Expenses | -4.6% | 72,001,000 | 75,490,000 | 73,490,000 | 70,821,000 | 60,798,000 | 54,228,000 | 53,951,000 | 43,535,000 | 35,183,000 | 29,611,000 | 28,350,000 | 25,338,000 | 20,249,000 | 19,779,000 | 18,046,000 | 12,232,500 | 10,685,000 | 9,894,000 | 9,762,000 | 6,373,000 | 5,313,000 |
| R&D Expenses | -7.6% | 114,766,000 | 124,187,000 | 126,683,000 | 141,236,000 | 131,076,000 | 128,339,000 | 130,976,000 | 153,839,000 | 116,109,000 | 134,575,000 | 104,071,000 | 82,705,000 | 79,853,000 | 65,083,000 | 71,708,000 | 62,940,500 | 47,362,000 | 38,324,000 | 34,240,000 | 26,758,000 | 23,626,000 |
| EBITDA Margin | - | - | - | -39.01 | -59.30 | - | - | - | -173 | -106 | -107 | -107 | -107 | -104 | -63.94 | -63.94 | -63.94 | -15.70 | -18.64 | - | - | - |
| Income Taxes | - | - | - | - | 254,000 | 254,000 | - | - | - | 3,299,000 | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings Before Taxes | - | - | - | - | -202,221,000 | -173,307,000 | - | - | -199,620,000 | -76,755,000 | - | - | -101,087,000 | -87,336,000 | - | - | - | - | - | - | - | - |
| EBT Margin | - | - | - | -39.18 | -59.53 | - | - | - | -173 | -106 | -107 | -107 | -107 | -104 | -63.94 | -63.94 | -63.94 | -15.70 | -18.64 | - | - | - |
| Net Income | 8.5% | -161,904,000 | -176,913,000 | -184,586,000 | -202,475,000 | -173,561,000 | -176,445,000 | -188,386,000 | -199,620,000 | -80,054,000 | -166,430,000 | -135,680,000 | -101,087,000 | -87,336,000 | -82,859,000 | -86,655,000 | -72,376,000 | -54,273,000 | -45,695,000 | -40,912,000 | -28,272,000 | -27,568,000 |
| Net Income Margin | - | - | - | -39.01 | -59.57 | - | - | - | -174 | -144 | -147 | -122 | -107 | -98.72 | -88.80 | -77.66 | -63.94 | -26.99 | -26.98 | - | - | - |
| Free Cashflow | - | - | - | -190,451,000 | -129,610,000 | -139,049,000 | -145,153,000 | -161,609,000 | -140,634,000 | -49,041,000 | -97,397,000 | -111,523,000 | -77,927,000 | -78,199,000 | -60,544,000 | -59,228,000 | -43,234,000 | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Assets | 23.5% | 1,130 | 915 | 1,034 | 1,203 | 1,303 | 1,280 | 1,421 | 1,589 | 1,253 | 1,356 | 1,381 | 1,476 | 620 | 664 | 713 | 432 | 471 | 501 | 309 | 228 | 248 |
| Current Assets | 26.5% | 1,036 | 819 | 939 | 1,109 | 1,226 | 1,203 | 1,343 | 1,508 | 1,172 | 1,278 | 1,304 | 1,404 | 595 | 654 | 705 | 424 | 465 | 496 | 306 | 227 | 246 |
| Cash Equivalents | 99.7% | 259 | 130 | 242 | 235 | 299 | 266 | 305 | 414 | 243 | 281 | 330 | 886 | 131 | 132 | 205 | 47.00 | 92.00 | 252 | 75.00 | 33.00 | 117 |
| Inventory | 133.2% | 20.00 | 9.00 | 4.00 | 3.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net PPE | -4.9% | 16.00 | 17.00 | 17.00 | 18.00 | 18.00 | 17.00 | 17.00 | 16.00 | 14.00 | 12.00 | 9.00 | 8.00 | 6.00 | 3.00 | 2.00 | 2.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Liabilities | -1.5% | 183 | 186 | 171 | 206 | 174 | 168 | 172 | 192 | 169 | 227 | 121 | 115 | 69.00 | 59.00 | 57.00 | 50.00 | 36.00 | 29.00 | 26.00 | 27.00 | 23.00 |
| Current Liabilities | -1.9% | 137 | 140 | 125 | 159 | 127 | 119 | 124 | 144 | 122 | 181 | 77.00 | 71.00 | 67.00 | 58.00 | 56.00 | 49.00 | 35.00 | 28.00 | 25.00 | 26.00 | 22.00 |
| Shareholder's Equity | 29.8% | 946 | 729 | 863 | 997 | 1,129 | 1,112 | 1,249 | 1,397 | 1,084 | 1,129 | 1,259 | 1,361 | 551 | 605 | 656 | 382 | 434 | 472 | 284 | 202 | 225 |
| Retained Earnings | -5.8% | -2,976 | -2,814 | -2,637 | -2,452 | -2,250 | -2,076 | -1,900 | -1,712 | -1,512 | -1,432 | -1,265 | -1,130 | -1,029 | -941 | -858 | -772 | -699 | -645 | -599 | -559 | -530 |
| Additional Paid-In Capital | 10.7% | 3,924 | 3,545 | 3,502 | 3,453 | 3,386 | 3,185 | 3,145 | 3,100 | 2,587 | 2,552 | 2,516 | 2,481 | 1,570 | 1,535 | 1,505 | 1,145 | 1,124 | 1,108 | 874 | 751 | 746 |
| Shares Outstanding | 20.2% | 70.00 | 58.00 | 58.00 | 58.00 | 58.00 | 56.00 | 55.00 | 55.00 | 52.00 | 51.00 | 51.00 | 50.00 | 45.00 | 44.00 | 43.00 | 40.00 | 37.00 | 36.00 | 35.00 | 31.00 | 30.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Quarterly) | (In Thousands) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Cashflow From Operations | -9.4% | -143,713 | -131,400 | -190,182 | -128,800 | -137,809 | -143,492 | -160,469 | -137,985 | -47,032 | -93,367 | -110,416 | -76,421 | -76,763 | -59,343 | -59,004 | -41,902 | -32,874 | -38,468 | -34,482 | -20,795 | -20,172 |
| Share Based Compensation | 13.1% | 44,553 | 39,399 | 46,961 | 61,607 | 42,992 | 38,684 | 42,905 | 33,878 | 26,933 | 27,969 | 24,722 | 21,743 | 21,750 | 20,787 | 21,567 | 16,711 | 15,106 | 12,589 | 11,131 | 4,262 | 4,058 |
| Cashflow From Investing | -500.4% | -62,194 | 15,532 | 195,151 | 59,297 | 13,945 | 103,006 | 49,555 | -170,838 | 704 | 36,761 | -455,528 | -59,340 | 64,157 | -22,447 | -122,227 | -6,939 | -128,066 | -5,927 | -35,208 | -63,683 | 28,762 |
| Cashflow From Financing | 8609.3% | 334,700 | 3,843 | 1,727 | 5,920 | 157,105 | 1,392 | 2,527 | 479,282 | 8,232 | 7,823 | 9,885 | 889,889 | 12,351 | 9,273 | 339,201 | 3,473 | 1,072 | 221,882 | 111,601 | 462 | 2,157 |
MRTX Income Statement
2023-09-30CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
| Total revenue | $ 16,400 | $ 5,431 | $ 37,257 | $ 11,502 |
| Revenue | ||||
| Total revenue | 16,400 | 5,431 | 37,257 | 11,502 |
| Operating expenses | ||||
| Cost of product revenue | 1,428 | 0 | 3,011 | 0 |
| Cost of product revenue - intangible asset amortization | 259 | 0 | 776 | 0 |
| Research and development | 114,766 | 131,076 | 365,636 | 390,391 |
| Selling, general and administrative | 72,001 | 60,798 | 220,981 | 168,977 |
| Total operating expenses | 188,454 | 191,874 | 590,404 | 559,368 |
| Loss from operations | (172,054) | (186,443) | (553,147) | (547,866) |
| Other income, net | 10,150 | 13,136 | 29,744 | 9,728 |
| Loss before income taxes | (161,904) | (173,307) | (523,403) | (538,138) |
| Income tax expense | 0 | 254 | 0 | 254 |
| Net loss | (161,904) | (173,561) | (523,403) | (538,392) |
| Unrealized gain (loss) on available-for-sale investments | 106 | (1) | 2,175 | (5,712) |
| Foreign currency translation adjustment | 59 | (9,485) | (6) | (9,485) |
| Comprehensive loss | $ (161,739) | $ (183,047) | $ (521,234) | $ (553,589) |
| Basic net loss per share (USD per share) | $ (2.49) | $ (3.09) | $ (8.66) | $ (9.66) |
| Diluted net loss per share (USD per share) | $ (2.49) | $ (3.09) | $ (8.66) | $ (9.66) |
| Weighted average common shares outstanding, basic (shares) | 64,993,079 | 56,219,416 | 60,419,755 | 55,747,205 |
| Weighted average common shares outstanding, diluted (shares) | 64,993,079 | 56,219,416 | 60,419,755 | 55,747,205 |
| Product Revenue | ||||
| Total revenue | $ 16,400 | $ 0 | $ 36,056 | $ 0 |
| Revenue | ||||
| Total revenue | 16,400 | 0 | 36,056 | 0 |
| License and Collaboration Revenue | ||||
| Total revenue | 0 | 5,431 | 1,201 | 11,502 |
| Revenue | ||||
| Total revenue | $ 0 | $ 5,431 | $ 1,201 | $ 11,502 |
MRTX Balance Sheet
2023-09-30CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets | ||
| Cash and cash equivalents | $ 258,718 | $ 235,260 |
| Short-term investments | 717,716 | 848,577 |
| Accounts receivable, net | 14,651 | 865 |
| Inventory | 20,156 | 3,020 |
| Other current assets | 24,839 | 21,239 |
| Total current assets | 1,036,080 | 1,108,961 |
| Property and equipment, net | 16,046 | 17,540 |
| Intangible asset, net | 14,138 | 14,914 |
| Long-term investment | 3,559 | 3,465 |
| Right-of-use asset | 35,066 | 36,122 |
| Other long-term assets | 24,819 | 21,645 |
| Total assets | 1,129,708 | 1,202,647 |
| Current liabilities | ||
| Accounts payable | 37,961 | 38,861 |
| Accrued liabilities | 99,418 | 120,587 |
| Total current liabilities | 137,379 | 159,448 |
| Lease liability | 42,203 | 43,661 |
| Other liabilities | 3,661 | 3,022 |
| Total liabilities | 183,243 | 206,131 |
| Commitments and contingencies (see Note 11) | ||
| Shareholders' equity | ||
| Preferred stock, $0.001 par value, 10,000,000 shares authorized; none issued and outstanding at both September 30, 2023 and December 31, 2022 | 0 | 0 |
| Common stock, $0.001 par value; 100,000,000 authorized; 70,111,309 and 57,854,559 issued and outstanding at September 30, 2023 and December 31, 2022, respectively | 70 | 58 |
| Additional paid-in capital | 3,924,237 | 3,453,066 |
| Accumulated other comprehensive loss | (1,550) | (3,719) |
| Accumulated deficit | (2,976,292) | (2,452,889) |
| Total shareholders' equity | 946,465 | 996,516 |
| Total liabilities and shareholders' equity | $ 1,129,708 | $ 1,202,647 |
| Â CEO | Dr. Charles M. Baum M.D., Ph.D. |
|---|---|
| Â WEBSITE | www.mirati.com |
| Â EMPLOYEES | 587 |